Navigation Links
New gateway to treat leukemia and other cancers
Date:3/25/2010

This press release is available in French.

Montreal, March 25, 2010 Canadian researchers have discovered a previously hidden channel to attack leukemia and other cancer cells, according to a new study published in the Journal of Biological Chemistry. The findings from the Universit de Montral, Maisonneuve-Rosemont Hospital and Universit Laval may change the way doctors treat cancer patients.

"We found a gateway, which is present in all humans, that allows anti-cancer agents such as Bleomycin to enter the body so they may reach and attack leukemia cells," says senior author Dindial Ramotar, a professor at the Universit de Montral Faculty of Medicine and a scientist at the affiliated Maisonneuve-Rosemont Hospital.

Dr. Ramotar began testing his theory a full decade ago using baker's yeast, which is remarkably similar to human cells. "Our discovery went from that model system to human cells and will soon reach the bedside through translational therapy," he explains. "We are on the brink of testing patients."

The new gateway (SLC22A16) may be a lifesaver for patients with acute myeloid leukemia (AML), a cancer that affects white blood cells. AML patients are extremely difficult to treat, since most are unresponsive to anticancer remedies. "We can now streamline anti-cancer agents to treat AML," says Dr. Ramotar. "For example, we found the anti-cancer agent Bleomycin has positive results on lymphoma cells derived from patients and depends on the presence of the gateway. That's especially good news, since Bleomycin does not act as an immunosuppressant."

The newly identified gateway, Dr. Ramotar cautions, is only "present in some cell types such as those derived from bone marrow." The channel also does not function in colon and breast cancer making it difficult to treat these patients with Bleomycin, he adds. "We must now examine ways to stimulate the gateway to treat a broad range of cancers using Bleomycin and other drugs."


'/>"/>

Contact: Sylvain-Jacques Desjardins
sylvain-jacques.desjardins@umontreal.ca
514-343-7593
University of Montreal
Source:Eurekalert

Related medicine news :

1. BMEGateway Celebrates its 20th Anniversary and Welcomes Dr. William Morgan
2. Technology new gateway into treatment for problem alcohol users: Study
3. Djigzo, an Open Source Email Encryption Provider, Today Announced That the Company's Encryption Gateway Now Supports Red Hat Linux
4. Michigan Health Care Providers Select mPay Gateways Point-of-Care Patient Payment System
5. GateWay Community College Receives Strong Endorsement for Re-accreditation
6. Steroids May Be Overrated in Treatment of COPD
7. Untreated, Mild May Become Major Depression
8. Hard to Treat Diseases (HTDS) Comments on Recent Movement Of Its Security
9. Experimental stem cell treatment arrests acute lung injury in mice, study shows
10. American Association of Poison Control Centers: Treat Poinsettias and Mistletoe with Respect Rather Than Fear This Holiday Season
11. Entest BioMedical Enters into LOI with Advanced Light Devices to Develop Laser Platform for Stem Cell / Laser COPD Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... 07, 2016 , ... "Today, MHA and mental health advocates ... systems reform legislation in more than fifty years. We applaud the bipartisan action ... elected officials to improving mental health services and supports in our nation. , ...
(Date:12/7/2016)... ... December 07, 2016 , ... Children ... bodies, a researcher at the Icahn School of Medicine at Mount Sinai has ... found that when young children are exposed to secondhand marijuana smoke, measurable amounts ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... ... the release of Smart Device Remote Control through a new partnership with Splashtop ... platforms and strengthens its mobile solutions to help businesses maximize their uptime and ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... Presence Technology, S.L. (“Presence”) for a purchase price of approximately $17.4 million ... considerations. Presence’s annual revenue is approximately $13.2 million. Headquartered in Barcelona, Spain, ...
(Date:12/7/2016)... ... 07, 2016 , ... It is vital for any lab to secure funding, ... The team at Beckman Coulter has designed Kaluza, templates with advanced analytical tools to ... to operate in a GLP (Good Laboratory Practice) fashion. , With features designed to ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016 Henry Schein, Inc. (Nasdaq: ... care products and services to office-based dental, animal health and ... equity investment in Marrodent, one of Poland,s ... $32 million. This transaction was announced on August 30, 2016. ... Poland since 2014, and Marrodent marks ...
(Date:12/8/2016)... 2016 Research and Markets has announced the addition ... to their offering. ... The report provides separate comprehensive analytics for ... and Rest of World. Annual estimates and forecasts are ... is provided for these markets. Market data and analytics are derived from ...
(Date:12/7/2016)... -- "Lantus (Insulin Glargine) Biosimilar Clinical Trial & Opportunity Insight" report by ... drug in clinical pipeline. Currently 5 biosimilar version of Lantus are commercially ... Kenya , Czech Republic , ... , Slovakia , United Kingdom ... patent on Lantus expired in 2014. Lantus is the brand name ...
Breaking Medicine Technology: